Abstract
Prostate cancer is the second most common malignancy among men worldwide. However, conventional chemotherapy, such as taxane therapy, fails to exhibit efficient treatment for almost half of the patients. In this study, a nano-drug delivery system based on black phosphorus nanosheets (BP NSs) was developed, which was then employed as a multifunctional nanoplatform for targeted combinational chemo-photothermal therapy against prostate cancer. Zinc ion (Zn2+), which has been proven to be able to inhibit prostate cancer cell proliferation, was also introduced into this system. Zn2+ coordination could not only enhance the therapeutic effect of combined chemo-photothermal therapy, but also improve the intrinsic instability of BP NSs through the stabilization of its lone pair electrons. The in vivo study showed the outstanding performance of this system in targeted photothermal/chemotherapy of prostate cancer without side effect to normal organs.
Highlights
Prostate cancer is the second most common malignancy among men around the world (Heidenreich et al, 2014)
Zinc ion was conjugated to black phosphorus nanosheets (BP NSs) surface and the loading content of Zn2+ was about 12.8%
Anticancer drug DOX was loaded for chemotherapy with loading content (LC) of 15.2% (Supplementary Figure S2)
Summary
Prostate cancer is the second most common malignancy among men around the world (Heidenreich et al, 2014). Stage localized prostate cancer can be treated effectively by hormone and radiation therapy with less difficulty, the treatment of advanced-stage prostate cancer remains a significant challenge due to its frequent pathophysiological changes, epithelial-mesenchymal transition and drug resistance (Chen et al, 2018; Mollica et al, 2019; Wang et al, 2019c). Most patients with prostate cancer are already in late-stage at the time of consultation (Wang et al, 2019c; Teo et al, 2019). It is of great urgency to develop a high effective and relatively affordable method for the treatment of prostate cancer, especially late-stage prostate cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
